These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1243126)

  • 1. A new central direct dopaminergic stimulant: 1-(Coumaran-5-yl methyl)-4-(2-thiazolyl) piperazine hydrochloride (S 3608).
    Poignant JC; Gressier H; Petitjean M; Regnier G; Canevari R
    Experientia; 1975 Oct; 31(10):1204-5. PubMed ID: 1243126
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence that nigral GABA mediates behavioural responses elicited by striatal dopamine receptor stimulation.
    Di Chiara G; Morelli M; Porceddu ML; Gessa GL
    Life Sci; 1978 Nov; 23(20):2045-51. PubMed ID: 569236
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine and amphetamine stereotypy after 6-hydroxydopamine lesions of the substantia nigra.
    Price MT; Fibiger HC
    Eur J Pharmacol; 1974 Dec; 29(2):249-52. PubMed ID: 4613562
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions.
    Slater P; Crossman AR
    Neuropharmacology; 1980 Mar; 19(3):289-95. PubMed ID: 7191487
    [No Abstract]   [Full Text] [Related]  

  • 5. Proceedings: Differences in circling responses following electrolytic and 6-hydroxydopamine lesions of the nigro-striatal pathway.
    Costall B; Marsden CD; Naylor RJ; Pycock CJ
    Br J Pharmacol; 1975 Oct; 55(2):289P-290P. PubMed ID: 1238135
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for a role of endogenous opioids in the nigrostriatal system: influence of naloxone and morphine on nigrostriatal dopaminergic supersensitivity.
    Hirschhorn ID; Hittner D; Gardner EL; Cubells J; Makman MH
    Brain Res; 1983 Jun; 270(1):109-17. PubMed ID: 6409355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of lergotrile or apomorphine induced turning behavior by haloperidol and clozapine.
    Nakamura S; Engel J; Goldstein M
    Commun Psychopharmacol; 1978; 2(3):185-90. PubMed ID: 29742
    [No Abstract]   [Full Text] [Related]  

  • 8. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic effects of lergotrile: possible involvement of a metabolite.
    McDevitt JT; Setler PE
    Neuropharmacology; 1980 Jun; 19(6):537-42. PubMed ID: 6105627
    [No Abstract]   [Full Text] [Related]  

  • 10. Ergot alkaloids. New ergolines as selective dopaminergic stimulants.
    Stütz PL; Stadler PA; Vigouret JM; Jaton A
    J Med Chem; 1978 Aug; 21(8):754-7. PubMed ID: 567695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity?
    Creese I; Iversen SD
    Psychopharmacol Bull; 1975 Oct; 11(4):12-3. PubMed ID: 1197588
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes.
    Thal L; Mishra RK; Gardner EL; Horowitz SG; Varmuza S; Makman MH
    Brain Res; 1979 Jul; 170(2):381-6. PubMed ID: 572733
    [No Abstract]   [Full Text] [Related]  

  • 13. Potentiation of apomorphine-induced rotational behaviour by naloxone.
    Quock RM; Welsh TB
    J Pharm Pharmacol; 1981 Feb; 33(2):111-3. PubMed ID: 6111591
    [No Abstract]   [Full Text] [Related]  

  • 14. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD; Creese I
    Adv Neurol; 1975; 9():81-92. PubMed ID: 1170717
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopaminergic grafts in the striatum reduce D1 but not D2 receptor-mediated rotation in 6-OHDA-lesioned rats.
    Robertson GS; Fine A; Robertson HA
    Brain Res; 1991 Jan; 539(2):304-11. PubMed ID: 1675908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzamide potentiation of behavioral apomorphine-induced effects; mechanism involved.
    Piriou F; Petit JY; Welin L
    Experientia; 1985 Nov; 41(11):1409-10. PubMed ID: 2998860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway.
    Chopin P; Colpaert FC; Marien M
    J Pharmacol Exp Ther; 1999 Feb; 288(2):798-804. PubMed ID: 9918591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lesions of substantia nigra by kainic acid: effects on apomorphine-induced stereotyped behaviour.
    Morelli M; Porceddu ML; Di Chiara G
    Brain Res; 1980 Jun; 191(1):67-78. PubMed ID: 7189684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasticity of neostriatal dopamine receptors after nigrostriatal injury: relationship to recovery of sensorimotor functions and behavioral supersensitivity.
    Neve KA; Kozlowski MR; Marshall JF
    Brain Res; 1982 Jul; 244(1):33-44. PubMed ID: 6288182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.